Owned by the Association for the Promotion of International Tumor Studies
Articles
Page 1 of 83
-
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:152
-
ANXA1 promotes intrahepatic cholangiocarcinoma proliferation and growth by regulating glutamine metabolism through GOT1 stabilization
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor with a poor prognosis, marked by a postoperative recurrence rate of 50–60% and a 5-year survival rate of 8–30%. Abnormal tumor metabolism, particularl...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:151 -
Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma
Serous endometrial cancer (SEC) is a genomically and morphologically distinct endometrial cancer (EC) subtype with a poor progression-free and overall survival. The development of novel therapies is needed to ...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:150 -
Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation
Copper accumulation triggers mitochondrial-driven cell death, known as cuproptosis, offering a promising mechanism for targeted cancer therapy. Recent studies have highlighted the critical role of intratumoral...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:149 -
A novel pH-sensitive nanoparticles encapsulating anti-PD-1 antibody and MDK-siRNA overcome immune checkpoint blockade resistance in HCC via reshaping immunosuppressive TME
Immunotherapy, notably the immune checkpoint blockade (ICB), has demonstrated significant promise in the management of diverse neoplasms. However, the PD-1 inhibitor has exhibited suboptimal objective response...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:148 -
Light-activatable manganese carbonate nanocubes elicit robust immunotherapy by amplifying endoplasmic reticulum stress-meditated pyroptotic cell death
Although tumor immunotherapy has emerged as a promising treatment modality, it faces significant challenges stemming from the immunosuppressive characteristics of the tumor microenvironment (TME), the low immu...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:147 -
HBV-driven host chromatin accessibility changes affect liver metabolic pathways, iron homeostasis and promote a preneoplastic phenotype
Complex host-virus interactions account for adaptive and innate immunity dysfunctions and viral cccDNA mini-chromosome persistence, key features of HBV chronicity and challenges for HBV cure. The extent of HBV...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:146 -
Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy
Despite the significant advances in the development of immune checkpoint inhibitors (ICI), primary and acquired ICI resistance remains the primary impediment to effective cancer immunotherapy. Residing in the ...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:145 -
Genome-Wide Methylation Sequencing to Identify DNA Methylation Markers for Early-stage Hepatocellular Carcinoma in Liver and Blood
Hepatocellular carcinoma (HCC) is associated with a poor 5-year survival mainly due to detection at late stages. Better non-invasive surveillance methods are needed to improve early detection and maximize surv...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:144 -
Comparative analysis of circulating tumor cells in prostatic plexus and peripheral blood of patients undergoing prostatectomy
The potential influence of radical prostatectomy on tumor cell release into the blood circulation is an under-investigated area.
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:143 -
Tie2 activity in cancer associated myofibroblasts serves as novel target against reprogramming of cancer cells to embryonic-like cell state and associated poor prognosis in oral carcinoma patients
Myofibroblastic cancer-associated fibroblasts (CAF) in tumor stroma serves as an independent poor prognostic indicator, supporting higher stemness in oral cancer; however, the underlying biology is not fully c...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:142 -
Tumor cell-intrinsic BIN1 deficiency promotes the immunosuppression and impedes ferroptosis of non-small cell lung cancer via G3BP1-mediated degradation of STAT1
Tumors often evade immune surveillance by limiting T cell infiltration. In non-small cell lung cancer (NSCLC), increased infiltration of CD8+ T cells is associated with a favorable response to immunotherapy. Whil...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:141 -
Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice
Liquid biopsy offers a noninvasive method to identify and monitor tumor-derived biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, microRNAs, and tumor-educated plat...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:140 -
Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications
Lenvatinib, a tyrosine kinase receptor inhibitor, has emerged as a frontline therapeutic strategy for the management of advanced hepatocellular carcinoma (HCC). However, the modest response rate observed with ...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:139 -
Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy
Extracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability to modulate immune responses and deliver therapeutic agents...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:138 -
Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma
IL-33 is an epithelial-derived alarmin with various roles in cancer. In melanoma, endogenous and exogenous IL-33 exert anti-tumor effects through the stimulation of several immune effector cells. In this study...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:137 -
Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients
There are no validated biomarkers for assessing hepatocellular carcinoma (HCC) treatment response (TR). Extracellular vesicles (EVs) are promising circulating biomarkers that may detect minimal residual diseas...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:136 -
Epithelial-to-mesenchymal transition drives cancer genomic instability
Epithelial-to-Mesenchymal Transition (EMT) is a form of embryonic cell plasticity reactivated in adult cells during injury and cancer. A recent study by Perelli et al. demonstrates that EMT confers an evolutio...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:135 -
Red blood cell-tumor cell interactions promote tumor cell progression
A critical step in the metastatic cascade is the survival of circulating tumor cells (CTCs) within the bloodstream. Although interactions between CTCs and various hematopoietic cells have been described, the r...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:134 -
Targeting the HLA-E–NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG
Diffuse midline glioma (DMG) is an aggressive pediatric brain tumor with limited treatment options. Although natural killer (NK) cell-based immunotherapy is promising, its efficacy remains limited, necessitati...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:133 -
7aaRGD - a novel SPP1/integrin signaling-blocking peptide reverses immunosuppression and improves anti-PD-1 immunotherapy outcomes in experimental gliomas
Immune checkpoint inhibitors (ICIs) present clinical benefits in many cancer patients but invariably fail in glioblastoma (GBM), the most common and deadly primary brain tumor. The lack of ICIs efficacy in GBM...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:132 -
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy
This review discusses reprogramming the breast tumor immune microenvironment from an immunosuppressive cold state to an immunologically active hot state. A complex interplay is revealed, in which the accumulat...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:131 -
Exploring RNA binding proteins in hepatocellular carcinoma: insights into mechanisms and therapeutic potential
Hepatocellular carcinoma (HCC), the most prevalent type of primary liver cancer, is linked to elevated global incidence and mortality rates. Elucidating the intricate molecular pathways that drive the progress...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:130 -
A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is among the cancer types with poorest prognosis and survival rates primarily due to resistance to standard-of-care therapies, including gemcitabine (GEM) and olaparib. ...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:129 -
Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy
Lung cancer remains one of the most challenging diseases to treat due to its heterogeneity. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutations are genetic drivers in numerous cancer types including lu...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:128 -
Cancer-associated fibroblasts as a potential novel liquid biopsy marker in cancer patients
Cancer-associated fibroblasts (CAFs) are tissue residing cells within the tumor microenvironment (TME). Stromal CAFs have been shown to be associated with poor prognosis and tumor progression in several solid ...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:127 -
MicroRNA in cancer therapy: breakthroughs and challenges in early clinical applications
MicroRNAs (miRNAs) have emerged as pivotal regulators in cancer biology, influencing tumorigenesis, progression, and resistance to therapy. Their ability to modulate multiple oncogenic and tumor-suppressive pa...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:126 -
The de novo DNA methyltransferase 3B is a novel epigenetic regulator of MYC in multiple myeloma, representing a promising therapeutic target to counter relapse
The plasma cell malignancy multiple myeloma (MM) remains incurable due to the inevitable development of drug resistance (DR). Epigenetic modifiers are frequently mutated or deregulated in MM patients, contribu...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:125 -
Digital PCR-based genetic profiling from vitreous fluid as liquid biopsy for primary uveal melanoma: a proof-of-concept study
Uveal melanoma is an aggressive ocular malignancy. Early molecular characterisation of primary tumours is crucial to identify those at risk of metastatic dissemination. Although tumour biopsies are being taken...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:124 -
Correction: ELK3-CYFIP2 axis-mediated actin remodeling modulates metastasis and natural killer cell responses in triple-negative breast cancer
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:123 -
Correction: The anti-tumor efficacy of CDK4/6 Inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:122 -
LINC02167 stabilizes KSR1 mRNA in an m5C-dependent manner to regulate the ERK/MAPK signaling pathway and promotes colorectal cancer metastasis
Metastasis is a leading cause of colorectal cancer (CRC)-related mortality, yet its molecular mechanisms remain poorly understood. Long noncoding RNAs (lncRNAs) have emerged as critical regulators of CRC metas...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:121 -
Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer
Intrinsic and acquired resistance to second-generation anti-androgens pose a significant clinical challenge in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Novel biomarkers to pred...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:120 -
Metabolomic signatures in liquid biopsy are associated with overall survival in metastatic melanoma patients treated with immune checkpoint inhibitor therapy
Immune checkpoint inhibitors (ICIs), such as anti-Cytotoxic T-Lymphocyte Antigen 4(CTLA-4) and anti-Programmed cell death protein 1 (PD-1) agents, have improved the prognosis of patients with metastatic melano...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:119 -
Natural killer cells: the immune frontline against circulating tumor cells
Natural killer (NK) play a key role in controlling tumor dissemination by mediating cytotoxicity towards cancer cells without the need of education. These cells are pivotal in eliminating circulating tumor cel...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:118 -
Reduction of alternative polarization of macrophages by short-term activated hepatic stellate cell-derived small extracellular vesicles
Activated hepatic stellate cells (HSCs) induce alternative (M2) polarization of macrophages and contribute to the progression of fibrosis and hepatocellular carcinoma (HCC). However, the effects of small extra...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:117 -
Correction: TSPAN18 facilitates bone metastasis of prostate cancer by protecting STIM1 from TRIM32-mediated ubiquitination
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:116 -
Correction: Proteomic profiling and functional analysis of extracellular vesicles from metastasis-competent circulating tumor cells in colon cancer
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:115 -
Tetrahydrobenzimidazole TMQ0153 targets OPA1 and restores drug sensitivity in AML via ROS-induced mitochondrial metabolic reprogramming
Acute myeloid leukemia (AML) is a highly aggressive cancer with a 5-year survival rate of less than 35%. It is characterized by significant drug resistance and abnormal energy metabolism. Mitochondrial dynamic...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:114 -
CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype
Regulatory T cells (Tregs) are the main immunosuppressive cells in tumor immune microenvironment (TIME). However, systemic Treg depletion is not favored due to the crucial role of Tregs in the maintenance of i...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:113 -
TRAF7 knockdown induces cellular senescence and synergizes with lomustine to inhibit glioma progression and recurrence
The progression and recurrence are the fatal prognostic factors in glioma patients. However, the therapeutic role and potential mechanism of TRAF7 in glioma patients remain largely unknown.
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:112 -
Transcriptional profiles of circulating tumor cells reflect heterogeneity and treatment resistance in advanced prostate cancer
New biomarkers for the detection and monitoring of aggressive variant prostate cancer (AVPC) including therapy-induced neuroendocrine prostate cancer (NEPC) are urgently needed, as measuring prostate-specific ...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:111 -
o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis
Lung cancer is a serious threat to human life and health, but effective screening and treatment methods are lacking. Circular RNAs (circRNAs) have important biological functions and are closely related to tumo...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:110 -
Role of inflammasomes in cancer immunity: mechanisms and therapeutic potential
Inflammasomes are multi-protein complexes that detect pathogenic and damage-associated molecular patterns, activating caspase-1, pyroptosis, and the maturation of pro-inflammatory cytokines such as IL-1β and I...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:109 -
C-FOS promotes the formation of neutrophil extracellular traps and the recruitment of neutrophils in lung metastasis of triple-negative breast cancer
Neutrophil extracellular traps (NETs) are composed of DNA chains from neutrophils and associated proteolytic enzymes, which play an important role in cancer metastasis. However, the molecular mechanism of NET-...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:108 -
Innovative dual-gene delivery platform using miR-124 and PD-1 via umbilical cord mesenchymal stem cells and exosome for glioblastoma therapy
Addressing the challenges of identifying suitable targets and effective delivery strategies is critical in pursuing therapeutic solutions for glioblastoma (GBM). This study focuses on the therapeutic potential...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:107 -
RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
KRAS is the most frequently mutated oncogene in human cancers, with KRASG12C being a prevalent driver mutation in 12–13% non-small cell lung cancer (NSCLC) cases. Despite breakthroughs in KRASG12C inhibitors such...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:106 -
Blood-based detection of MMP11 as a marker of prostate cancer progression regulated by the ALDH1A1-TGF-β1 signaling mechanism
Prostate cancer (PCa) is the second most common type of tumor diagnosed in men and the fifth leading cause of cancer-related death in male patients. The response of metastatic disease to standard treatment is ...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:105 -
AMP-activated protein kinase mediates adaptation of glioblastoma cells to conditions of the tumor microenvironment
AMP-activated protein kinase (AMPK) is an energy sensor that regulates cellular metabolic activity. We hypothesized that in glioblastoma (GB), AMPK plays a pivotal role in balancing metabolism under conditions...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:104 -
N4-acetylcytidine modification of ITGB5 mRNA mediated by NAT10 promotes perineural invasion in pancreatic ductal adenocarcinoma
Perineural invasion (PNI) is a hallmark feature of pancreatic ductal adenocarcinoma (PDAC), which occurs at a high incidence and significantly contributes to PDAC lethality and poor survival. Despite its preva...
Citation: Journal of Experimental & Clinical Cancer Research 2025 44:103
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 11.4
5-year Journal Impact Factor: 11.4
Source Normalized Impact per Paper (SNIP): 1.770
SCImago Journal Rank (SJR): 2.806Speed 2024
Submission to first editorial decision (median days): 2
Submission to acceptance (median days): 96Usage 2024
Downloads: 4,059,655
Altmetric mentions: 2,197